Gene Therapy

Gene therapy is the deliberate modification of a person's genetic material to treat, prevent, or cure disease, and it rests on the molecular biology established after the elucidation of DNA structure by Watson and Crick in 1953 and the development of recombinant DNA techniques by Cohen and Boyer in 1973. The first authorized human gene-transfer trial took place in the United States on 14 September 1990, when researchers at the National Institutes of Health treated a four-year-old girl, Ashanti DeSilva, for adenosine deaminase deficiency (ADA-SCID). In India the technique is governed by the Drugs and Cosmetics Act, 1940, read with the Rules of 1945, the National Guidelines for Gene Therapy Product Development and Clinical Trials issued by the Indian Council of Medical Research and the Department of Biotechnology in 2019, and the recombinant-DNA safety framework administered under the Environment (Protection) Act, 1986, through the Genetic Engineering Appraisal Committee and the Review Committee on Genetic Manipulation.

The procedural core of gene therapy is the delivery of a functional gene, or a gene-editing apparatus, into target cells. The clinician first identifies the defective or absent gene responsible for a monogenic disorder and synthesises a corrective transgene. This therapeutic cargo is then packaged into a vector — most commonly an adeno-associated virus (AAV), a lentivirus, or an adenovirus stripped of its pathogenic replication capacity — which serves as a molecular delivery vehicle. The vector is introduced either directly into the patient's body or into cells extracted from the patient. Once inside the nucleus or cytoplasm, the transgene either integrates into the host chromosome or persists as an episome, after which the cell's own machinery transcribes and translates it into the missing protein, restoring function.

Two delivery strategies define the field. In in vivo therapy the vector is administered directly to the patient, as with intravenous or intraocular injection, allowing it to find its target tissue within the body. In ex vivo therapy clinicians harvest the patient's cells — typically haematopoietic stem cells or T lymphocytes — correct them in the laboratory, expand them in culture, and reinfuse them; chimeric antigen receptor (CAR) T-cell cancer treatments follow this route. A further and more consequential distinction is between somatic gene therapy, which alters non-reproductive cells and is not heritable, and germline gene therapy, which modifies eggs, sperm, or embryos and is transmitted to descendants. India's 2019 guidelines, like the regulatory position of most jurisdictions, permit somatic interventions for research and therapy while prohibiting germline modification for reproductive purposes.

Contemporary milestones illustrate the technology's maturation. The European Medicines Agency approved Glybera in 2012 as the first gene therapy licensed in a Western market. The United States Food and Drug Administration approved Luxturna for inherited retinal dystrophy in December 2017 and the spinal-muscular-atrophy therapy Zolgensma in May 2019, the latter priced above two million dollars. On 16 November 2023 the United Kingdom's Medicines and Healthcare products Regulatory Agency authorised Casgevy, the first CRISPR-based therapy, for sickle-cell disease and beta-thalassaemia, with the FDA following in December 2023. In India, the Centre for Stem Cell Research at Christian Medical College Vellore and the inStem–CSCR consortium in Bengaluru have advanced indigenous CRISPR and gene-therapy programmes for haemoglobinopathies, supported by the Department of Biotechnology.

Gene therapy must be distinguished from adjacent concepts with which it is frequently conflated. It differs from genetic engineering of crops or microorganisms, which alters non-human organisms for agricultural or industrial ends and falls under the GEAC's biosafety mandate. It is narrower than gene editing, a set of tools such as CRISPR-Cas9, zinc-finger nucleases, and TALENs that can serve gene therapy but also basic research and diagnostics. It is conceptually opposite to reproductive cloning, which copies an entire genome rather than correcting a defect, and it should not be confused with stem-cell therapy, which transplants cells without necessarily altering their DNA, though the two increasingly converge in ex vivo protocols.

The field carries unresolved controversies. The death of eighteen-year-old Jesse Gelsinger in a 1999 Pennsylvania trial exposed the immunogenic dangers of viral vectors and reshaped trial oversight. In November 2018 the Chinese scientist He Jiankui announced the birth of twins whose embryos he had edited with CRISPR, a germline intervention that drew global condemnation and a three-year prison sentence, prompting the World Health Organization to establish a registry and advisory committee on human genome editing. Persistent concerns include insertional mutagenesis that can trigger leukaemia, off-target edits, the durability of expression, and equity of access given the extraordinary prices of approved products. The prospect of enhancement rather than therapy — selecting for intelligence, height, or other non-disease traits — sustains an active bioethical debate over the boundary between cure and design.

For the working practitioner, gene therapy sits at the intersection of health policy, biotechnology regulation, intellectual property, and security governance. Civil-services aspirants encounter it in General Studies Paper III under science and technology, where the somatic–germline distinction, the role of the ICMR, DBT, and GEAC, and the 2019 national guidelines are examinable specifics. Foreign-policy desks track it within biosecurity frameworks, the Biological Weapons Convention's dual-use concerns, and global access negotiations at the WHO. As India pursues affordable indigenous therapies for thalassaemia and sickle-cell disease — the latter a National Health Mission priority — officials must weigh innovation incentives against pricing, informed consent, and the ethical lines that domestic law and international consensus now draw around heritable modification.